JTE-162 is under clinical development by Japan Tobacco and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how JTE-162’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JTE-162 overview
JTE-162 is under development for the treatment of autoinflammatory disease and autoimmune disease. The therapeutic candidate acts by targeting NACHT LRR And PYD Domains Containing Protein 3 (NLRP3) and is administered through oral route.
Japan Tobacco overview
Japan Tobacco (JT Group) is a manufacturer of tobacco. The company’s primary activities include the manufacture and sale of tobacco products, the research and development of pharmaceuticals, and the production of processed foods. Its major products encompass a wide range of tobacco brands, frozen noodles, prescription drugs, packaged cooked rice, seasoning, and frozen and ambient processed foods. The company’s brands include Winston, Camel, and Mevius in the tobacco sector. It has presence in markets such as Japan, France, Germany, Italy, the Philippines, Taiwan, Jordan, Kazakhstan, and Romania. JT Group is headquartered in Minato-ku, Tokyo, Japan.
For a complete picture of JTE-162’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
